SPRINT Trial: Lower Blood Pressure Target May Prevent Cardiovascular Events
A systolic blood pressure target of 120 mm Hg vs 140 mm Hg may prevent cardiovascular events and reduce mortality, according to results from the SPRINT trial.
AHA2015
Nitric Oxide With Prolonged Cardiopulmonary Bypass May Help Prevent Acute Kidney Injury
Using nitric oxide during and after prolonged cardiopulmonary bypass may prevent acute kidney injury.
Novel Agent Reversed Anticoagulant Effects of Rivaroxaban in Older Healthy Patients
Andexanet alfa reversed anticoagulant effects of rivaroxaban in older healthy patients without clinical toxic effects.
Decrease in Ideal Cardiovascular Health Among American Adults
Despite progress in heart disease, the number of adults achieving ideal cardiovascular health, as defined by the American Heart Association’s Simple 7 health metrics, has decreased.
Liraglutide Did Not Improve Clinical Stability in Advanced Heart Failure, Reduced LVEF
Liraglutide failed to improve post-hospitalization clinical stability in patients with advanced heart failure and reduced left ventricular ejection fraction.
Candesartan May Be Cardioprotective in Women With Breast Cancer Treated with Adjuvant Therapy
Breast cancer patients may benefit from concomitant treatment with candesartan to prevent decline in global left ventricular function.
Left Ventricular Augmentation With Algisyl May Benefit Heart Failure Patients
Algisyl may be more effective when added to standard medical therapy vs standard medical therapy alone for heart failure patients.
Mirabegron Failed to Improve Left Ventricular Ejection Fraction in Chronic Heart Failure vs Placebo
Results from BEAT-HF trial show mirabergron in patients with chronic heart failure failed to improve left ventricular ejection fraction.
Ranolazine Did Not Improve Angina, Myocardial Perfusion Index in Certain Patients with Microvascular Dysfunction
In the RWISE study, ranolazine did not improve SAQ angina or myocardial perfusion index in patients with microvascular dysfunction.
Heart Failure Hospitalizations, CV Death Reduced With Empagliflozin
Results from the EMPA-REG OUTCOME trial showed empagliflozin reduced heart failure hospitalizations and cardiovascular deaths in patients with type 2 diabetes.
- Loading...
Loading...
Next post in AHA Meeting Highlights
Loading... 
Loading...